elacestrant
oral, non-steroidal SERD/SERM approved for ER+, HER2-, mESR1 adv./metastatic BC degrades ERɑ in dose-dependent manner FDA approval, January 27, 2023 Eisai, Tokyo, JP (Stemline/Menarini)
Molecules of the Month - January 2023
oral, non-steroidal SERD/SERM approved for ER+, HER2-, mESR1 adv./metastatic BC degrades ERɑ in dose-dependent manner FDA approval, January 27, 2023 Eisai, Tokyo, JP (Stemline/Menarini)
Molecules of the Month - January 2023